Floatz logo

ibi305

Hepatocellular Carcinoma

Innovent Biologics (Suzhou) Co. Ltd.monoclonal_antibodyPhase 2/3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
81/ 100

Competitive context

521 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Theprubicin
RWTH Aachen University
Phase 4BB
nrt6003
Second Affiliated Hospital of Guangzhou Medical University
Phase 3BB
Inno-206
VA Office of Research and Development
Phase 4BB

View all 50 →

Same molecule, other indications

ibi305 is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
58 / 100
View asset →
colorectal cancerDormant
CCC
Indicative ·
53 / 100
View asset →
EGFR Mutant NSCLC and Platinum Resistant Ovarian CancerDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →